Biogen
ProfileJobs (391)

Biogen

Suggest Edit
    • Healthcarebiotechdrug developmentpharma
    Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
    Revenue(FY, 2016)
    $11.4 B
    Market capitalization(2018-09-19)
    $68.3 B
    Training Provided, no. of people(FY, 2016)
    40 K
    TypePublic
    HQCambridge, US
    Founded1978
    Size (employees)7,300 (est)-1%
    Websitebiogen.com
    Biogen was founded in 1978 and is headquartered in Cambridge, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Biogen

    Michel Vounatsos

    Michel Vounatsos

    CEO
    Susan Alexander

    Susan Alexander

    EVP
    Jeffrey Capello

    Jeffrey Capello

    EVP
    Michael Ehlers

    Michael Ehlers

    EVP
    Ginger Gregory

    Ginger Gregory

    EVP
    Chirfi Guindo

    Chirfi Guindo

    EVP
    Show more

    Biogen Office Locations

    Biogen has an office in Cambridge
    Cambridge, US (HQ)
    225 Binney St
    Show all (1)
    Report incorrect company information

    Biogen Financials and Metrics

    Biogen Revenue

    Biogen's revenue was reported to be $11.45 b in FY, 2016 which is a 6.4% increase from the previous period.
    USD

    Revenue (Q1, 2017)

    		2.8 b

    Net income (Q1, 2017)

    		747.5 m

    EBIT (Q1, 2017)

    		1 b

    Market capitalization (19-Sep-2018)

    		68.3 b

    Closing stock price (19-Sep-2018)

    		338.9

    Cash (31-Mar-2017)

    		924 m
    Biogen's current market capitalization is $68.3 b.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Revenue

    		6.9 b9.7 b10.8 b11.4 b

    Revenue growth, %

    		40%11%6%

    General and administrative expense

    		1.9 b

    R&D expense

    		2 b
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Revenue

    		2.4 b2.5 b2.6 b2.6 b2.8 b2.7 b2.9 b3 b2.8 b

    General and administrative expense

    		576.6 m570.4 m560.4 m491.9 m477.8 m497.3 m492.4 m462.7 m499.1 m

    R&D expense

    		447.3 m417.2 m460.5 m490.7 m519.9 m437.3 m473.1 m529 m423.4 m

    Operating expense total

    		1 b987.6 m1 b982.6 m997.7 m934.6 m965.5 m991.7 m922.5 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Cash

    		602.6 m1.2 b1.3 b2.3 b

    Accounts Receivable

    		824.4 m1.3 b1.2 b1.4 b

    Inventories

    		659 m804 m893.4 m1 b

    Current Assets

    		3.2 b4.7 b6.7 b8.7 b
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Cash

    		863.2 m1.2 b1.5 b1.3 b4.1 b1.1 b1.4 b2.1 b924 m

    Accounts Receivable

    		1 b1.1 b1.4 b1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b

    Inventories

    		715.9 m753.1 m825.3 m865.7 m918.9 m964.6 m996.4 m1 b921.6 m

    Current Assets

    		3.9 b4.4 b5.3 b5.6 b9.3 b7.2 b7.4 b8.1 b6.9 b
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    		1.9 b2.9 b3.6 b3.7 b

    Depreciation and Amortization

    		688.2 m600.4 m682.7 m

    Inventories

    		(240 m)(190 m)(170 m)(165.6 m)
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    		723.1 m856.1 m820.2 m924.8 m1 b969.2 m1 b1 b747.5 m

    Inventories

    		865.7 m918.9 m964.6 m996.4 m1 b921.6 m

    Accounts Payable

    		282.7 m251.2 m271.3 m225.9 m274 m316.4 m
    show all
    USDY, 2017

    Revenue/Employee

    		379.8 k

    Financial Leverage

    		1.8 x
    Show all financial metrics

    Biogen Operating Metrics

    Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
    FY, 2016

    Phase I Trials Products

    		4

    Phase II Trials Products

    		10

    Phase III Trials Products

    		2

    Training Provided, no. of people

    		40 k
    Show all operating metrics

    Biogen Acquisitions / Subsidiaries

    Acquired CompanyDateDeal Size
    AliveGenJuly 25, 2018$27.50 m
    Karyopharm TherapeuticsJanuary 25, 2018$10 m
    Report incorrect company information

    Competitors

    Shire
    Healthcare - Public
    Bayer
    Healthcare - Public
    Amgen
    Healthcare - Public
    Gilead Sciences
    Healthcare - Public
    Regeneron Pharmaceuticals
    Healthcare - Public
    Compare competitors

    Biogen Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Biogen News and Updates

    September 19, 2018

    Recombinant DNA Technology 2018 Global Market Key Players – Monsanto Company, Roche, Biogen, Amgen, Novartis, Eli Lilly and Company, GenScript – Analysis and Forecast to 2025

    WiseGuyRerports.com Presents “Global Recombinant DNA Technology Market Size, Status and Forecast 2018-2025” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday
    September 11, 2018

    Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022: Key Vendors are Biogen, F. Hoffmann-La Roche, Merck, Novartis & Spectrum Pharmaceuticals

    DUBLIN, Sept 11, 2018 /PRNewswire/ -- The "Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global B-Cell Non-Hodgkin Lymphoma Drugs Market to grow at a CAGR of 7.52% during the period 2018-2022. Global B-cell...
    September 04, 2018

    Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction

    CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) announced today the enrollment of the first patient in the global Phase 3 clinical study CHARM, designed to evaluate BIIB093 (intravenous (IV) glibenclamide) for the prevention and treatment of severe cerebral edema in larg…
    August 13, 2018

    Biogen's pricey muscle drug Spinraza too costly for Britain

    Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.
    August 09, 2018

    There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong

    Experts are questioning a major scientific theory of the disease, which could mean two Biogen drugs won’t be successful.
    August 03, 2018

    Biogen's stock gets a boost from new $3.5 billion stock repurchase program

    Shares of Biogen Inc. rose 0.6% in premarket trade Friday, after the biotechnology company disclosed the authorization of a $3.5 billion share repurchase program. In a filing with the Securities and Exchange Commission, the company said the repurchase program does not have an expiration date. The c…
    Show more
    Report incorrect company information

    Biogen Company Life and Culture

    Report incorrect company information
    Download PDF